ABBV AbbVie Inc

  1. Stocks
  2. Healthcare
  3. NYSE: ABBV

Price (delayed)

$146.725

Market cap

$258.98B

P/E Ratio

30.07

Dividend/share

$5.85

EPS

$4.88

Enterprise value

$311.23B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
The debt has declined by 16% year-on-year
The EPS has contracted by 31% YoY but it has grown by 15% from the previous quarter
The company's net income fell by 31% YoY but it rose by 15% QoQ
ABBV's P/E is 19% above its 5-year quarterly average of 25.5 and 13% above its last 4 quarters average of 26.8
AbbVie's equity has decreased by 12% YoY and by 3.1% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.abbvie.com/
Peers: PFE BMY LLY AMGN

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$258.98B
Enterprise value
$311.23B
Valuations
Price to earnings (P/E)
30.07
Price to book (P/B)
20.12
Price to sales (P/S)
4.63
EV/EBIT
25.25
EV/EBITDA
14.77
EV/Sales
5.56
Earnings
Revenue
$56.02B
EBIT
$12.32B
EBITDA
$21.07B
Free cash flow
$24.8B
Per share
EPS
$4.88
Free cash flow per share
$14.03
Book value per share
$7.29
Revenue per share
$31.71
TBVPS
$22.8
Balance sheet
Total assets
$135.37B
Total liabilities
$122.47B
Debt
$61.02B
Equity
$12.87B
Working capital
-$3.39B
Liquidity
Debt to equity
4.74
Current ratio
0.89
Quick ratio
0.63
Net debt/EBITDA
2.48
Margins
EBITDA margin
37.6%
Gross margin
68.9%
Net margin
15.5%
Operating margin
31%
Efficiency
Return on assets
6.3%
Return on equity
58.5%
Return on invested capital
19.3%
Return on capital employed
12%
Return on sales
22%
Dividend
Dividend yield
3.99%
DPS
$5.85
Payout ratio
119.9%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
-1.03%
1 week
-4.67%
1 month
-1%
1 year
6.08%
YTD
-9.21%
QTD
-1.57%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$56.02B
Gross profit
$38.61B
Operating income
$17.39B
Net income
$8.69B
Gross margin
68.9%
Net margin
15.5%
The company's net income fell by 31% YoY but it rose by 15% QoQ
The net margin has declined by 30% year-on-year but it rose by 16% since the previous quarter
The operating margin rose by 9% since the previous quarter and by 2.3% year-on-year
The operating income has grown by 8% from the previous quarter

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
ABBV P/E details
P/E
30.07
P/B
20.12
P/S
4.63
EV/EBIT
25.25
EV/EBITDA
14.77
EV/Sales
5.56
The EPS has contracted by 31% YoY but it has grown by 15% from the previous quarter
ABBV's P/E is 19% above its 5-year quarterly average of 25.5 and 13% above its last 4 quarters average of 26.8
ABBV's price to book (P/B) is 14% higher than its last 4 quarters average of 17.8
AbbVie's equity has decreased by 12% YoY and by 3.1% from the previous quarter
ABBV's P/S is 14% above its 5-year quarterly average of 4.1
ABBV's revenue is down by 2.3% year-on-year

Efficiency

How efficient is AbbVie business performance
The ROE has contracted by 31% YoY but it has grown by 18% from the previous quarter
AbbVie's return on assets has decreased by 28% YoY but it has increased by 17% QoQ
The ROS has contracted by 23% YoY but it has grown by 14% from the previous quarter
AbbVie's ROIC has increased by 16% from the previous quarter but it has decreased by 14% YoY

Dividends

What is ABBV's dividend history
Dividend details
DPS
$5.85
Dividend yield
3.99%
Payout ratio
119.9%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 11% higher than its total liabilities
ABBV's current ratio is down by 7% since the previous quarter but it is up by 6% year-on-year
AbbVie's total assets has decreased by 5% YoY
The debt has declined by 16% year-on-year
AbbVie's equity has decreased by 12% YoY and by 3.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.